Activating transcription factor 2 antibody, Activating transcription factor 2 splice variant ATF2 var2 antibody, ATF 2 antibody, Atf-2 antibody, Atf2 antibody, ATF2 protein antibody, ATF2_HUMAN antibody, cAMP Response Element Binding Protein 2 antibody, cAMP response element binding protein CRE BP1 antibody, cAMP response element-binding protein CRE-BP1 antibody, cAMP responsive element binding protein 2, formerly antibody, cAMP-dependent transcription factor ATF-2 antibody, cAMP-responsive element-binding protein 2 antibody, CRE BP1 antibody, CRE-BP antibody, CREB 2 antibody, CREB-2 antibody, CREB2 antibody, CREBP1 antibody, Cyclic AMP dependent transcription factor ATF 2 antibody, Cyclic AMP-dependent transcription factor ATF-2 antibody, Cyclic AMP-responsive element-binding protein 2 antibody, D130078H02Rik antibody, D18875 antibody, HB 16 antibody, HB16 antibody, Histone acetyltransferase ATF2 antibody, MGC105211 antibody, MGC105222 antibody, MGC111558 antibody, MGC142504 antibody, mXBP antibody, MXBP protein antibody, Tg(Gzma-Klra1)7Wum antibody, TREB 7 antibody, TREB7 antibody |
The transcription factor ATF2 is a member of the ATF/CREB family of leucine zipper proteins. In response to stress stimuli, it activates a variety of gene targets that are involved in oncogenesis, and has been correlated with maintenance of a cancer cell phenotype (Vlahopoulos et al., 2008). Inhibiting ATF2 impedes melanoma development and elicits tumor suppressor function (Bhoumik et al., 2008). To act as a tumor suppressor, ATF2 must localize at the mitochondria, and phosphorylation at Thr-52 by PKCε regulates this translocation (Lau et al., 2012). |